Limits...
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.

Sankin A, Hakimi AA, Hsieh JJ, Molina AM - Front Oncol (2015)

Bottom Line: Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway.The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care.This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

View Article: PubMed Central - PubMed

Affiliation: Memorial Sloan-Kettering Cancer Center , New York, NY , USA.

ABSTRACT
Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

No MeSH data available.


Related in: MedlinePlus

Kaplan–Meier estimates of overall survival in all patients with clear cell histology vs non-clear cell histology.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4389537&req=5

Figure 1: Kaplan–Meier estimates of overall survival in all patients with clear cell histology vs non-clear cell histology.

Mentions: Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that the diversity of renal tumors is not just limited to their biologic blueprints, but is reflected in its behavior, which impacts clinical outcomes as well (28). nccRCC patients had a significantly worse overall survival than their clear cell counterparts (12.8 vs 22.3 months, respectively) (Figure 1). The nccRCC patients were then subdivided into specific histologies, revealing the best survival among patients with chromophobe tumors, followed by papillary tumors, and then unclassified.


Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.

Sankin A, Hakimi AA, Hsieh JJ, Molina AM - Front Oncol (2015)

Kaplan–Meier estimates of overall survival in all patients with clear cell histology vs non-clear cell histology.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4389537&req=5

Figure 1: Kaplan–Meier estimates of overall survival in all patients with clear cell histology vs non-clear cell histology.
Mentions: Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that the diversity of renal tumors is not just limited to their biologic blueprints, but is reflected in its behavior, which impacts clinical outcomes as well (28). nccRCC patients had a significantly worse overall survival than their clear cell counterparts (12.8 vs 22.3 months, respectively) (Figure 1). The nccRCC patients were then subdivided into specific histologies, revealing the best survival among patients with chromophobe tumors, followed by papillary tumors, and then unclassified.

Bottom Line: Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway.The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care.This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

View Article: PubMed Central - PubMed

Affiliation: Memorial Sloan-Kettering Cancer Center , New York, NY , USA.

ABSTRACT
Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

No MeSH data available.


Related in: MedlinePlus